复方氨基酸注射液(20AA)规范化应用及效果分析  

Standardized Process and Effect Analysis of the Compound Amino Acid Preparation(20AA)

作　　者：卞晓洁[1] 杨靓靓[1] 于冬悦 刘金永[1] 葛卫红[1] 

机构地区：[1]南京大学医学院附属鼓楼医院药学部,南京210008

出　　处：《药学与临床研究》2015年第4期407-409,共3页Pharmaceutical and Clinical Research

摘　　要：目的:明确复方氨基酸注射液(20AA)合理使用方法,提高含该制剂肠外营养处方合格率。方法:制定本院《20AA适用规范》,明确20AA仅适用于临床诊断为肝脏疾病或存在肝功能不全需使用静脉营养支持者;继而淘汰用量畸高厂家的品种,由临床药师对20AA用药进行干预。结果与结论:含20AA处方数占总肠外营养处方数由干预前的66.59%下降为22.29%,总超适应证不合格率由干预前的59.17%下降为33.33%,干预成功率由干预前的0%上升为10.3%。20AA的药学干预取得良好效果。Objective: To seek the rational practice of the compound amino acid preparation (20AA), and to improve the qualified rate of the parenteral nutritional prescriptions containing this preparation. Methods: A hospital "20AA applicable norms" was drafted demanding that 20AA should only be applied to intravenous nutritional support for clinically diagnosed liver disease or dysfunction. Then one extremely overprescribed 20AA product was sifted out, and all the prescriptions were continually intervened by clini-cal pharmacists. Results and conclusion: The 20AA prescriptions in the treatment of total parenteral nu-trition were decreased from 66.59% to 22.29%, the rate of overprescription was decreased from 59.17% to 33.33% after the intervention, and the success rate was raised from 0% to 10.3%. Rational use of 20AA was achieved by pharmaceutical intervention.

关 键 词：复方氨基酸注射液(20AA) 规范化 多重药学干预 处方合格率 

分 类 号：R977.9[医药卫生—药品]